These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23252570)

  • 1. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
    Gallucci G; Tartarone A; Tocchetti CG; Bochicchio AM; Coccaro M; Capobianco A; Maurea N; Improta G; Zupa A; Aieta M
    Future Oncol; 2013 Jan; 9(1):127-33. PubMed ID: 23252570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
    Telli ML; Witteles RM; Fisher GA; Srinivas S
    Ann Oncol; 2008 Sep; 19(9):1613-8. PubMed ID: 18436521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.
    Dong Z; Gao J; Gong J; Li J; Li Y; Shen L; Li J
    Future Oncol; 2017 Oct; 13(23):2035-2043. PubMed ID: 28685593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK; Jarkowski A
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
    Chorianopoulos E; Jäger D; Katus HA; Frey N
    Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
    Chu TF; Rupnick MA; Kerkela R; Dallabrida SM; Zurakowski D; Nguyen L; Woulfe K; Pravda E; Cassiola F; Desai J; George S; Morgan JA; Harris DM; Ismail NS; Chen JH; Schoen FJ; Van den Abbeele AD; Demetri GD; Force T; Chen MH
    Lancet; 2007 Dec; 370(9604):2011-9. PubMed ID: 18083403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
    Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib.
    Heng DY; Kollmannsberger C
    Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
    Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib in solid tumors.
    Gan HK; Seruga B; Knox JJ
    Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
    Zhu X; Stergiopoulos K; Wu S
    Acta Oncol; 2009; 48(1):9-17. PubMed ID: 18752081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.